NIH funding opportunities

Faculty of Medicine and Health Sciences: Research Development and Support 22 Aug 2016 (#28)

[Click on blue hyperlink for further information]

*The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov.*

*Please be advised that you **must contact the Research Grants Management Office (RGMO) Pre-Awards** (Dr Christa Coetsee cdevries@sun.ac.za) **as soon as possible to inform of your intent to apply and then confirm at least 30 days before the submission date**. The NIH grant is submitted institutionally. **All final application documents MUST reach the RGMO seven (7) workdays before NIH application due date.***

Important notices

- **Reminder: NIH Natural Disaster Policy (NOT-OD-16-135)**
- **Notice of Correction Regarding Foreign Institutions for PAR-16-301 "Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24)" (NOT-HL-16-337)**

1. Kidney Precision Medicine Project Recruitment Sites

Letter of Intent due date: 30 days prior to the application due date **Hyperlink:** (RFA-DK-16-026) **Type: UG3/UH3**
Application Due Date: December 6, 2016. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (to both Grants.gov and eRA Commons) on the application due date.
Purpose: This Funding Opportunity Announcement (FOA) requests applications for the Kidney Precision Medicine Project (KPMP) Recruitment Sites (RS) to recruit participants with either acute kidney injury (AKI) or chronic kidney disease (CKD) into longitudinal cohort studies. The RS will collaborate with the KPMP Tissue Interrogation Sites and Central Hub to obtain and evaluate kidney biopsies from participants, create a kidney tissue atlas, define disease subgroups, and identify critical cells, pathways and targets for novel therapies. Applicants should propose to study either AKI or CKD, outline initial cohorts of interest, provide inclusion/exclusion criteria, and estimate recruitment targets given the FOA budget and KPMP objectives. Applicants should have documented experience with patient recruitment and safely obtaining kidney biopsies for clinical and/or research purposes. The initial UG3 exploratory phase will be used to demonstrate that the site can recruit and follow a sufficient number of well-characterized participants with either AKI or CKD, and safely obtain high-quality research kidney biopsies while conforming to the highest ethical, research and clinical standards. UG3 projects that have met their milestones will be administratively considered by the NIDDK and prioritized for transition to the UH3 implementation phase. UH3 awards will support continued recruitment into larger cohort studies. Applicants to this FOA must address both the UG3 and UH3 phases. This FOA is intended to support only human studies and applications that include animal or model systems are not responsive.
Budget: NIDDK intends to commit $6,750,000 in FY 2017 to support three related funding opportunities, RFA-DK-16-026, RFA-DK-16-027, and RFA-DK-16-028. We anticipate awarding 1 Central Hub, 3-5 Recruitment Sites, and 4-5 Tissue Interrogation Sites. Application budgets are not limited but need to reflect the actual needs of the proposed project. The direct costs for UG3 awards are expected to be approximately $200,000-$300,000 per year. The direct costs for UH3 awards are expected to be approximately $400,000-$600,000 per year. The UG3 phase is limited to two years. The UH3 phase is limited to three years.

2. Kidney Precision Medicine Project Tissue Interrogation Sites

Letter of Intent due date: 30 days prior to the application due date **Hyperlink:** (RFA-DK-16-027) **Type: UG3/UH3**
Application Due Date: December 6, 2016. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (to both Grants.gov and eRA Commons) on the application due date.
Purpose: This Funding Opportunity Announcement (FOA) requests applications for the Kidney Precision Medicine Project (KPMP) Tissue Interrogation Sites (TIS) to use and develop innovative technologies to analyze human kidney tissue. The TIS will collaborate with the KPMP Recruitment Sites and Central Hub to obtain and evaluate kidney biopsies from participants with acute kidney injury and chronic kidney disease, create a kidney tissue atlas, define disease subgroups, and identify critical cells, pathways and targets for novel therapies. Applicant teams should have documented experience with a current state-of-the-art method that can be used or adapted to interrogate human kidney tissue. The initial UG3 exploratory phase will be used to demonstrate that the site can interrogate existing tissue samples and small numbers of new biopsies. The UG3 phase will also encourage the development of next generation tissue interrogation technologies that probe the structural, functional and molecular complexities of kidney tissue. UG3 projects that have met their milestones will be administratively considered by the NIDDK and prioritized for transition to the UH3 implementation phase. UH3 awards will support further validation, scale-up and technology development. Applicants must address both the UG3 and UH3 phases. This FOA is intended to support only human studies and applications that include animal or model systems are not responsive.
Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The direct costs for UG3 awards are expected to be approximately $200,000-$300,000 per year. The direct costs for UH3 awards are expected to be approximately $400,000-$600,000 per year. The UG3 phase is limited to two years. The UH3 phase is limited to three years.

3. NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) Genetic Research Centers (GRCs)

Letter of Intent due date: 30 days prior to the application due date **Hyperlink:** (RFA-DK-16-029) **Type: U01**

Application Due Date: December 14, 2016. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (to both Grants.gov and eRA Commons) on the application due date.

Purpose: The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) was established in July, 2002 for the purpose of identifying genes predisposing to IBD. Since its establishment, the IBDGC, in collaboration with the International IBD Genetics Consortium, has identified about 200 such susceptibility loci. However, most of these loci include multiple genes, and for the great majority of the loci, specific causal genes and alleles have not yet been identified. The mechanisms by which the most of the causative genes influence IBD pathophysiology also remain unknown. The purpose of this FOA is to renew the IBDGC to identify risk-conferring and protective variants of causal genes for IBD, and to elucidate the mechanisms by which these variants influence the pathophysiology of IBD. The GRCs will serve as sites of enrollment of IBD patients, relatives, and healthy controls for these studies, and for laboratory-based studies on biological samples taken from these subjects. The Program Directors/Principal Investigators of the GRCs will serve as members of the Steering Committee of the IBDGC, which will be responsible for all of the IBDGC's operational decisions, which will be binding upon all of the IBDGC's members.

Budget: NIDDK intends to commit $2,624,000 in FY 2017 to fund 6 awards. Application budgets are limited to $293,000 (direct costs) per year. The maximum project period is 5 years.

4. Limited Competition for the Continuation of the Hepatitis B Research Network Clinical Centers

Letter of Intent due date: 30 days prior to the application due date **Hyperlink:** (RFA-DK-16-512) **Type: U01**

Application Due Date: December 19, 2016. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (to both Grants.gov and eRA Commons) on the application due date.

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to continue the Hepatitis B Research Network Clinical Centers with a focus on the promotion of translational research on hepatitis B focusing upon elucidating the pathogenesis and natural history and developing means of treatment and control.

Budget: The NIDDK intends to commit $7 million dollars in FY 2017 to support the continuation of the Hepatitis B Research Network, as embodied in RFA-DK-14-506, RFA-DK-14-510 and this FOA. It is expected that up to a total of 10 non-competitive Renewal and New meritorious awards will be supported in FY 2017 under these three FOAs. It is anticipated that up to one award will be made under the current announcement. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 3 years.

5. BRAIN Initiative: Foundations of Non-Invasive Functional Human Brain Imaging and Recording - Bridging Scales and Modalities

Letter of Intent due date: 30 days prior to the application due date **Hyperlink:** (RFA-MH-17-235) **Type: R01**

Application Due Date: November 23, 2016. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (to both Grants.gov and eRA Commons) on the application due date.

Purpose: This funding opportunity announcement (FOA), in support of the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative®, aims to support transformative discoveries that will lead to breakthroughs in understanding human brain function. Guided by the long-term scientific plan, "BRAIN 2025: A Scientific Vision," this FOA specifically seeks to support efforts that will revolutionize our understanding of the biological activity underlying, and bioinformatic content of, data collected using contemporary non-invasive functional brain imaging techniques. The hope is that these transformative discoveries will lead to breakthroughs in understanding the dynamic activity of the human brain.

Budget: Issuing IC and partner components intend to commit an estimated total of $5 million to fund 10 awards. Application budgets are limited to $700,000 in direct costs (including consortium F&A) in any project year, and need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 4 years.

6. Understanding and Addressing the Multi-level Influences on Uptake and Adherence to HIV Prevention Strategies Among Adolescent Girls and Young Women in Sub-Saharan Africa

Letter of Intent due date: 30 days prior to the application due date **Hyperlink:** (RFA-MH-17-550) **Type: R01**
(RFA-MH-17-555) **R21**

Application Due Date: December 20, 2016. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (to both Grants.gov and eRA Commons) on the application due date.

Purpose: This initiative aims to: (1) enhance our understanding of the multi-level factors that influence HIV prevention strategy use among adolescent girls and young women (AGYW) in sub-Saharan Africa and (2) develop and test novel interventions to address these factors and enhance the uptake and adherence to HIV prevention strategies among AGYW in sub-Saharan Africa. The goal of this initiative is to look at the multiple levels of influence on AGYW's behavior from the individual level, to her partners, family members and peers as well as cultural, social norms and structural factors that may influence uptake and adherence to prevention strategies.

Budget: NIMH intends to fund an estimate of 4-6 awards for this FOA and the companion FOAs, corresponding to a total of $2,000,000, for fiscal year 2017. Future year amounts will depend on annual appropriations. NICHD intends to fund an estimate of 2-3 awards for a total of-$1,000,000 for this FOA and the companion R21 FOA for fiscal year 2017. Exact amounts will depend on annual appropriations. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. **R21**-The combined budget for direct costs for the two year project period may not exceed $275,000. No more than $200,000 may be requested in any single year.

7. NLM Express Research Grants in Biomedical Informatics

Letter of Intent due date: N/A **Hyperlink:** (PAR-16-404) **Type: R01**

Application Due Date: Standard dates & Standard AIDS dates Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (to both Grants.gov and eRA Commons) on the application due date.

Purpose: The National Library of Medicine (NLM) offers support for innovative research in biomedical informatics and data science. The scope of NLM's interest in the research domain of informatics is broad and interdisciplinary, developing methods and approaches in biomedical computing, data science and related information fields for application domains of health and biomedicine, including health care delivery, basic biomedical research, clinical and translational research, precision medicine, public health, biosurveillance, health information management in disasters, and similar areas. NLM defines biomedical informatics as the science of optimal representation, organization, management, integration and presentation of information relevant to human health and biology, for purposes of learning, sharing and use.

Budget: The NLM Express Research Grant has a limit of $250,000 per year in direct costs. The scope of the proposed project should determine the project period. The maximum project period is 4 years.

8. Single-Site Investigator-Initiated Clinical Trials

Letter of Intent due date: 30 days prior to the application due date **Hyperlink:** (PAR-16-405) **Type: R61/R33**

Application Due Date: November 10, 2016; February 14, 2017; June 14, 2017; October 11, 2017; February 13, 2018; June 14, 2018; October 11, 2018; February 13, 2019; June 14, 2019. **Aids Application Due dates:** January 11, 2017; May 12, 2017; September 13, 2017; January 11, 2018; May 14, 2018; September 13; 2018; January 11, 2019; May 13, 2019; September 13, 2019. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (to both Grants.gov and eRA Commons) on the application due date.

Purpose: This Funding Opportunity Announcement (FOA) supports applications to develop and implement phase II and beyond investigator-initiated single-site clinical trials. Applications submitted to this FOA must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website: http://www.nhlbi.nih.gov. This FOA will utilize a bi-phasic, milestone-driven mechanism of award. It is anticipated that applications will present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes the conduct of the trial, as well as plans for project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. The multiple PD/PI model is strongly encouraged but not required. Applicants are encouraged to include a PD/PI with expertise in biostatistics, clinical trial design, and coordination. Due to the complex nature of conducting a clinical trial, applicants are strongly encouraged to contact the appropriate Scientific/Research contact prior to submitting an application. Staff will be able to assist applicants in meeting the objectives of this FOA.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum period of the combined R61 and R33 phases is 5 years, with up to 1 year for the R61 phase and up to 4 years for the R33 phase. The scope of the proposed project should determine the requested project period.

9. Planning Grant for Emerging Epidemic Virus Research Training for West African Countries with Widespread Transmission of Ebola- Guinea, Liberia, and Sierra Leone

Letter of Intent due date: 30 days prior to the application due date **Hyperlink:** (PAR-16-407) **Type: D71**

Application Due Date: February 22, 2017. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (to both Grants.gov and eRA Commons) on the application due date.

Purpose: This Funding Opportunity Announcement invites applications from U.S. or African research institutions to plan research training and capacity building programs focused on emerging viral epidemics in collaboration with institutions in Guinea, Liberia, and/or Sierra Leone. The application should propose a collaborative planning process to develop training approaches that will create sustainable research capacity for the early identification, transmission prediction, testing of public health responses, and assessing and addressing long term health sequelae related to emerging viral diseases that have the potential for regional and global pandemics.

Budget: Application budgets are limited to a maximum of $50,000 total costs. The maximum project period is one year.

10. NIDCR Small Grant Program for New Investigators

Letter of Intent due date: 30 days prior to the application due date **Hyperlink:** (PAR-16-409) **Type: R03**

Application Due Date: Standard dates & Standard AIDS dates Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (to both Grants.gov and eRA Commons) on the application due date.

Purpose: National Institute of Dental and Craniofacial Research Small Grant Program for New Investigators supports basic and clinical research conducted by scientists who are in the early stages of establishing an independent research career in oral, dental and craniofacial research. This R03 program supports pilot or feasibility studies and developmental research projects with the intention of obtaining sufficient preliminary data for a subsequent investigator- initiated Research Project Grant (R01) or equivalent application.

Budget: A budget for direct costs of up to $200,000 may be requested. Application budgets should not exceed $100,000 in direct costs in either year. The total project period may not exceed two years.

Brief definitions of some NIH grant mechanisms: *comprehensive list of extramural grant and cooperative agreement activity codes*

D71 - International Research Training Planning Grant: To plan for the preparation of an application for a D43 international research training grant or for a U2R international research training cooperative agreement.

D43 - International Research Training Grants: To support research training programs for US and foreign professionals and students to strengthen global health research and international research collaboration.

R01 – NIH Research Project Grant Program: most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <$500,000 p.a. (direct costs).

R21 – NIH Exploratory/Developmental Research Grant: encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <$275,000 (direct costs).

R03 – NIH Small Grant Program: limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, small-contained research projects, development of new research technology, etc.; normally for "new investigators"; not renewable; up to 2 years; budget generally <$50,000 (direct costs).

R21/R33 - Phased Innovation: The R33 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the R21 mechanism. Although only R21 awardees are generally eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under R33.

R25 – NIH Education Projects: used in a wide variety of ways to promote an appreciation for and interest in biomedical research, provide additional training in specific areas, and/or to develop ways to disseminate scientific discovery into public health and community applications.

R34 - Clinical Trial Planning Grant Program: To provide support for the initial development of a clinical trial, including the establishment of the research team; the development of tools for data management and oversight of the research; the development of a trial design and other essential elements of the study, such as the protocol, recruitment strategies, and procedure manuals; and to collect feasibility data.

R35 - Outstanding Investigator Award: To provide long term support to an experienced investigator with an outstanding record of research productivity. This support is intended to encourage investigators to embark on long-term projects of unusual potential.

U01 – NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

U24 – Resource-Related Research Projects – Cooperative Agreements: To support research projects contributing to improvement of the capability of resources to serve biomedical research.

U01 – NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

U19 - **Research Program-Cooperative Agreements:** supports a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach. A cooperative agreement research program generally involves the organized efforts of large groups, members of which are conducting research projects designed to elucidate the various aspects of a specific objective.

Glossary of selected acronyms:

FOA Funding Opportunity Announcement

PA Program Announcements *(click on "PA" to search for further funding opportunities)*

RFA Request for Applications *(click on "RFA" to search for further funding opportunities)*

Complete Glossary and acronym list of NIH Terms